Clinical Laboratory, The First People's Hospital of Huaihua of University of South China, Huaihua, Hunan, China.
Central Laboratory, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, Hainan, China.
J Cell Biochem. 2019 Dec;120(12):19796-19809. doi: 10.1002/jcb.29285. Epub 2019 Jul 24.
Bladder urothelial carcinoma is a malignant tumor with a high incidence in the uropoietic system. Considerable studies have shown that long noncoding RNA (lncRNA) plays an important role in the development and progression of bladder urothelial carcinoma. In this study, the lncRNA expression and clinical data of 377 bladder urothelial carcinoma patients were obtained from The Cancer Genome Atlas database and differentially expressed lncRNAs in cancer and normal groups were evaluated. Univariate COX and multivariate COX regression analyses of prognosis were performed on differentially expressed lncRNAs in the training data sets, six prognosis-related lncRNAs (LINC02195, LINC01484, LINC01468, SMC2-AS1, AC011298.1, and PTPRD-AS1) were assessed, and a six-lncRNA signature was constructed. The predictive capability of this six-lncRNA signature was validated in the testing data sets and entire data sets. The prognostic ability of the six-lncRNA signature was independent of other clinical elements after multivariate COX regression and stratified analyses of with other clinical elements. We performed functional enrichment analysis with the six prognosis-related lncRNAs. Results of functional enrichment revealed that these prognosis-related lncRNAs might promote the development and metastasis of bladder urothelial carcinoma. In summary, the six-lncRNA signature that we developed could effectively predict the prognosis of bladder urothelial carcinoma patients. This six-lncRNA signature might be a novel independent prognostic marker of bladder urothelial carcinoma. Moreover, it also provides novel insights into the mechanism of bladder urothelial carcinoma.
膀胱尿路上皮癌是一种在泌尿生殖系统中发病率较高的恶性肿瘤。大量研究表明，长链非编码 RNA（lncRNA）在膀胱尿路上皮癌的发生发展中发挥着重要作用。本研究从癌症基因组图谱数据库中获取了 377 例膀胱尿路上皮癌患者的 lncRNA 表达和临床数据，评估了癌组织和正常组织中差异表达的 lncRNA。在训练数据集上对差异表达的 lncRNA 进行单变量 COX 和多变量 COX 回归分析，筛选出 6 个与预后相关的 lncRNA（LINC02195、LINC01484、LINC01468、SMC2-AS1、AC011298.1 和 PTPRD-AS1），构建了一个六基因 lncRNA 特征模型。该六基因 lncRNA 特征模型在测试数据集和整个数据集上进行了验证。多变量 COX 回归和与其他临床因素的分层分析表明，该六基因 lncRNA 特征模型的预后能力独立于其他临床因素。我们对这 6 个与预后相关的 lncRNA 进行了功能富集分析。功能富集分析的结果表明，这些与预后相关的 lncRNA 可能促进了膀胱尿路上皮癌的发展和转移。综上所述，我们开发的六基因 lncRNA 特征模型可以有效地预测膀胱尿路上皮癌患者的预后。该六基因 lncRNA 特征模型可能是膀胱尿路上皮癌的一个新的独立预后标志物。此外，它还为膀胱癌的发病机制提供了新的见解。
